Sections
In 2025, AACR reported another year of positive operating returns. This financial stability enables AACR to comprehensively meet the challenges of the cancer problem. Operating revenues totaled $111 million and total expenditures were $101 million. The net impact of revenues and expenses resulted in an operating surplus of $47 million. As outlined in this report, several major projects were launched in 2025, and AACR was able to outperform the budget through successful programming, revenue growth, and prudent financial management.
Non-operating activities are primarily related to long-term investments. AACR’s investments provided strong returns in the amount of $37.5 million in 2025 and outperformed comparable market indexes.
As a result of the financial performance for the year 2025, AACR’s unrestricted net assets are now $252 million. These reserves ensure continued investment in the programs and initiatives that support AACR’s mission to prevent and cure all cancers.
Unrestricted Revenues and Expenses
As of December 31, 2025
| Projected 2025 | ||
| REVENUE | ||
| Membership Dues | $4,266,100 | |
| Scientific Meetings and Educational Workshops | $35,032,483 | |
| Publications | $20,212,528 | |
| Other Revenue | $6,533,933 | |
| Subtotal Program Revenue | $66,045,044 | |
| Support | ||
| NIH Grants | $468,506 | |
| Contributions | $44,200,768 | |
| Subtotal Support Revenue | $44,669,274 | |
| TOTAL REVENUE | $110,714,318 | |
| EXPENSES | ||
| Scientific Meetings and Educational Workshops | $27,471,002 | |
| Research Grants and Scientific Awards | $19,393,976 | |
| Scientific Publications | $13,564,531 | |
| Professional Education and Scientific Programs | $12,862,216 | |
| Communications, Science Policy and Patient Education | $10,887,396 | |
| Member Services | $3,162,082 | |
| Subtotal Program Services | $87,341,203 | |
| Support Services | $6,848,711 | |
| Fundraising and Development | $6,720,630 | |
| Subtotal Supporting Services | $13,569,341 | |
| TOTAL EXPENSES | $100,910,544 | |
| Operating Surplus before Investments | $9,803,774 | |
| Other Changes | ||
| Investment Income/(loss) | $37,480,280 | |
| Subtotal Other Changes | $37,480,280 | |
| Change in Unrestricted Net Assets | $47,284,054 | |
| NET ASSETS BEGINNING OF YEAR | $204,766,077 | |
| NET ASSETS END OF YEAR | $252,050,131 |
